Oncology
Penile Carcinoma
7
Pipeline Programs↗
1
Active Trials↗
7
Companies Involved↗
Penile Carcinoma is an early-stage landscape with 7 programs across 7 companies. The most active players are Glaxo Dba Glaxosmithkline, Novartis, Pfizer.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 27
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
8programs
Small molecule450%
Monoclonal antibody338%
Antibody–drug conjugate113%
Modality classified for 100% of 8 pipeline programs.
Analysis
Trial Status
4
clinical trials
Terminated1 · 25%
Recruiting1 · 25%
Unknown status1 · 25%
Withdrawn1 · 25%
Clinical Trials
Trial Activity
Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma
Unknown status·—·Phase 2·NCT03774901·32 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)